Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | BCL3 | P20749 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463572 | 0.85 | HTT (0.70) | TDP1MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL4710843 | 0.84 | TP53 (0.69) | TDP1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL14855912 | 0.83 | L3MBTL1 (0.61) | TDP1MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL13316080 | 0.82 | PDCD1 (0.66) | MEN1KMT2APDCD1CD274HTT | |
| SCHEMBL27471728 | 0.81 | MEN1 (0.74) | TDP1MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL31098214 | 0.81 | HTT (0.73) | TDP1MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL2606255 | 0.81 | NPC1 (0.64) | PDCD1CD274LMNAALDH1A1GLA | |
| SCHEMBL11284668 | 0.81 | PDCD1 (0.64) | MEN1KMT2APDCD1CD274ALDH1A1 | |
| SCHEMBL14252955 | 0.80 | PDCD1 (0.72) | TDP1MEN1KMT2APDCD1CD274 | |
| SCHEMBL16431496 | 0.80 | BCL3 (0.62) | TDP1MEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1603908-B1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1603908-B1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1603908-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004081009-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFBR2, TGFB2 | TDP1 3339/4885MEN1 1065/4885KMT2A 2127/4885 |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | TDP1 3721/4885MEN1 1681/4885KMT2A 1055/4885 |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | TGFB1, TGFB2, TGFBR1 | TDP1 3577/4885MEN1 853/4885KMT2A 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.